Two pioneering digital therapeutics (DTx) for addiction are available once again after their original developer Pear Therapeutics was dissolved last year.
Recent statistics from the NHS have highlighted an increase in prescribed medicine for attention deficit hyperactivity disorder (ADHD) over the past year,
NICE has followed through on plans to make a series of digital therapeutics (DTx) for adults with anxiety disorders or depression in England, although it acknowledges more
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.